BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 10492912)

  • 21. Measurement of activated protein C resistance during menstrual cycle in women with and without the Leiden mutation.
    Wramsby ML; Bremme K; Blombäck M
    Thromb Haemost; 2001 Apr; 85(4):614-8. PubMed ID: 11341494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
    De Bel AV; Van der Cruyssen GA; Devreese KM
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay.
    Gardiner C; Cohen H; Jenkins A; Machin SJ; Mackie IJ
    Blood Coagul Fibrinolysis; 2006 Sep; 17(6):477-83. PubMed ID: 16905952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma.
    Strobl FJ; Hoffman S; Huber S; Williams EC; Voelkerding KV
    Arch Pathol Lab Med; 1998 May; 122(5):430-3. PubMed ID: 9593344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activated protein C resistance: the influence of ABO-blood group, gender and age.
    Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L
    Thromb Res; 2006; 117(6):665-70. PubMed ID: 16023702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
    Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
    Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group.
    Rosén S; Johansson K; Lindberg K; Dahlbäck B
    Thromb Haemost; 1994 Aug; 72(2):255-60. PubMed ID: 7831662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A protein C pathway (PCP) screening test for the detection of APC resistance and protein C or S deficiencies.
    Haas FJ; van Sterkenburg-Kamp BM; Scheepers HA
    Semin Thromb Hemost; 1998; 24(4):355-62. PubMed ID: 9763352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Congenital resistance to activated protein C in patients with lupus anticoagulants: evaluation of two functional assays.
    Galli M; Duca F; Ruggeri L; Finazzi G; Negri B; Moia M
    Thromb Haemost; 1998 Aug; 80(2):246-9. PubMed ID: 9716147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
    Zangari M; Berno T; Zhan F; Boucher KM; Tricot G; Fink L
    Blood Coagul Fibrinolysis; 2011 Jul; 22(5):420-3. PubMed ID: 21537162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of sensitivity and specificity of confirmatory assays for lupus anticoagulant (LA) detection].
    Imoto K; Yasumuro Y; Taki M; Suzuki Y; Akatu S; Tajima C; Ichikawa Y
    Rinsho Byori; 1996 Aug; 44(8):797-801. PubMed ID: 8816068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnosis of thrombophilia based on coagulation and genetic studies].
    Bałszan-Kowalska I
    Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired APC resistance and oral contraceptives: differences between two functional tests.
    Curvers J; Thomassen MC; Nicolaes GA; Van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
    Br J Haematol; 1999 Apr; 105(1):88-94. PubMed ID: 10233368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Resistance to activated protein C--a novel cause of thrombophilia].
    Cycowitz Z; Seligsohn U; Zivelin A; Eldor A
    Harefuah; 1995 Jul; 129(1-2):1-5, 80. PubMed ID: 7557699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study.
    Toulon P; Smirnov M; Triscott M; Safa O; Biguzzi E; Bouziane K; Tripodi A
    Thromb Res; 2009 May; 124(1):137-43. PubMed ID: 19157524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME; Cabiedes J; Reyes E; Cabral AR
    Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor V Leiden in Greek thrombophilic patients: relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1 + 2.
    Lambropoulos AF; Foka Z; Makris M; Daly M; Kotsis A; Makris PE
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):485-9. PubMed ID: 9491265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detecting APC-resistant factor V: a functional method without plasma dilution.
    Rylatt DB; Hohnen-Behrens C; Pilgrim RL; Dickeson LE; Neal M; Exner T
    Blood Coagul Fibrinolysis; 1999 Sep; 10(6):359-66. PubMed ID: 10493217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical usefulness of global assays of the anticoagulant pathway of protein C].
    Toulon P
    Ann Biol Clin (Paris); 2001; 59(5):545-50. PubMed ID: 11602384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.